Genetic analysis of the catalytic domain of the GAP gene in human lung cancer cell lines.
Cell lines of non-small cell lung cancer (non-SCLC) have been shown to contain activating mutation of the K-ras oncogene in about 30% of cases, whereas no small cell lung cancer (SCLC) cell lines displayed these mutations. Biochemically, these mutations result in the ras gene product (p21) being constitutively activated in its GTP-bound form and insensitive to the hydrolytic action of the ras-specific GTPase-activating protein (ras GAP). We hypothesized that, if tumor development is related to the p21 ras being in the active GTP-bound state, then a similar malignant phenotype may result from an inactivating mutation in the ras GAP gene in the region that interacts with ras p21 (so-called catalytic domain). To test this hypothesis, we screened a panel of SCLC and non-SCLC cell lines for major genetic alterations in the catalytic domain of the GAP gene with the Southern blot technique, and for minor genetic abnormalities (e.g., point mutations) with denaturing gradient gel electrophoresis and single-strand conformation polymorphism. Mutations in the catalytic domain of the GAP gene could not be demonstrated by any technique in any cell line examined. We conclude that mutational inactivation of the catalytic domain of the GAP gene probably does not contribute to the development of lung cancer.
Mitsudomi
T
T
NCI-Navy Medical Oncology Branch, National Cancer Institute and National Naval Medical Center, Bethesda, MD 20889-5105.
Friedman
E
E
Gejman
P V
PV
McCormick
F
F
Gazdar
A F
AF
D015139:Blotting, Southern; D002289:Carcinoma, Non-Small-Cell Lung / Q000235:genetics*; D018288:Carcinoma, Small Cell / Q000235:genetics*; D002384:Catalysis; D002869:Chromosome Aberrations / Q000235:genetics; D025063:Chromosome Disorders; D004273:DNA, Neoplasm / Q000032:analysis; D004591:Electrophoresis, Polyacrylamide Gel; D020690:GTPase-Activating Proteins; D006801:Humans; D008175:Lung Neoplasms / Q000235:genetics*; D017354:Point Mutation; D016133:Polymerase Chain Reaction; D011506:Proteins / Q000235:genetics*; D016283:Proto-Oncogene Proteins p21(ras) / Q000235:genetics; D012334:RNA, Neoplasm / Q000032:analysis; D014407:Tumor Cells, Cultured; D020703:ras GTPase-Activating Proteins
D004273:DNA, Neoplasm; D020690:GTPase-Activating Proteins; D011506:Proteins; D012334:RNA, Neoplasm; D020703:ras GTPase-Activating Proteins; C501009:HRAS protein, human; D016283:Proto-Oncogene Proteins p21(ras)